Menu

Category: Research/Reports

340B Health, Researchers Spar over Biosimilar Study

Rich Daly Editor in Chief Views
Maureen Testoni headshot
Maureen Testoni, president and CEO of 340B Health, traded letters to the editor of Health Affairs over a 340B study published in May.
Researchers rejected criticism of a recent study in an academic journal they co-authored from the leader of a 340B hospital [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

340B Drug Purchases Reached $53.7 Billion in 2022, HRSA Data Show

Tom Mirga Editor at Large Views
Drug Channels Institute
Drug purchases under the 340B program totaled $53.7 billion in 2022, according to HRSA data obtained by Drug Channels.
Drug purchases under the 340B program totaled $53.7 billion in 2022, or 22.3% more than the $43.9 billion in 2021, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

Hospital 340B Sites increased by 400% Over 11 Years, Analysis Finds

Rich Daly Editor in Chief Views
Hospital building
A consulting firm analysis found that hospital 340B covered entity and child sites increased more than fourfold over the last 11 years.
Hospital 340B covered entity and child sites increased by more than 400% over the last 11 years, while the number [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

Expanding 340B Eligibility Could Double Program Size, Says Report

William Newton Washington Correspondent Views
IQVIA headquarters
An analysis from pharmaceutical research and data firm IQVIA projected the 340B program could more than double in size if patient eligibility expands.
The 340B program could more than double in size if the 340B patient definition expands, according to a recent report [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

Share of Retail Pharmacies that Contract with ‘Core’ 340B Safety-Net Facilities Fell Over Time, Study Finds

Tom Mirga Editor at Large Views
JAMA contract pharmacy study
There has been a decline in the share of retail pharmacies that contract with 340B "core safety-net facilities," according to a JAMA Health Forum study.
The proportion of retail contract pharmacies in the 340B program that contract exclusively with “core safety-net” facilities fell from 95% [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

340B Program Does Not Improve Hospital Inpatient Care for Medically Underserved Patients, HHS-Funded Study Finds

William Newton Washington Correspondent Views
Health Services Research study
A Health Services Research study with funding from a government agency suggested the 340B program does not improve hospital inpatient care quality.
The 340B drug pricing program does not improve inpatient care quality for underserved patients, a recent government-funded analysis concluded. A [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

Government Watchdog Reissues Controversial Finding on Adverse Incentives in 340B Program

William Newton Washington Correspondent Views
GAO 340B
GAO restated its controversial 2015 finding that 340B covered entities prescribe more drugs or more expensive drugs than necessary.
The U.S. Government Accountability Office late last month restated its controversial recommendation that Congress take actions to reduce incentives for [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

Hospitals Charge Average 500% of Top 20 Drug Costs, Says PhRMA-Funded Analysis

Rich Daly Editor in Chief Views
The Moran Company logo
A Moran Company study, funded by PhRMA, found 340B hospitals charge an average of 500% above acquisition costs for 20 high-cost drugs.
Hospitals charge, on average, 500% of their acquisition cost for 20 individual medicines that account for the largest share of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

On Deadline Day for Senate Feedback, Researchers in JAMA Urge 340B Provider Reporting, Tightening Eligibility, Preventing Drug Overcharges

Rich Daly Editor in Chief Views
JAMA 340B viewpoint
On the day a group of bipartisan Senators requested feedback from stakeholders, an influential academic and his colleagues published a series of recommendations to reform the 340B program in JAMA
A high-profile researcher and colleagues are urging a range of changes to the 340B program, including new provisions on transparency, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

Amid Historic Financial Challenges, 340B Proposed Payments Will ‘Make a Difference’ for Some Hospitals’ Budgets, Says Rating Official

Rich Daly Editor in Chief Views
Fitch Ratings webinar
A Fitch Ratings webinar on the not-for-profit hospital sector discussed the financial implications of the proposed $9 billion lump sum Medicare payment to make up for five years of illegal 340B cuts.
As the not-for-profit hospital sector slowly emerges from its worst financial year in recent history, some of those organizations’ bottom [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report